TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1434863

Group type: EXPERIMENTAL
Intervention: Epidural infusion of fentanyl citrate
Number of subjects: 66

Group type: COMPARATOR
Intervention: Patient-controlled intravenous administration of morphine
Number of subjects: 66
Study: 2864794

Group type: EXPERIMENTAL
Intervention: Mianserin 60 mg
Number of subjects: 61

Group type: COMPARATOR
Intervention: Nomifensine 100 mg
Number of subjects: 61
Study: 30721940

Group type: EXPERIMENTAL
Intervention: Individualized falls prevention education (tailored education comprising patient video and workbook, structured discussion and goal setting led by trained therapist)
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Individualized falls prevention education
Number of subjects: 382

Group type: COMPARATOR
Intervention: Control group (social intervention in addition to usual care)
Number of subjects: 382
Study: 29405603

Group type: EXPERIMENTAL
Intervention: Autologous umbilical cord blood (AUCB) infusion
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 26837052

Group type: EXPERIMENTAL
Intervention: Apremilast
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24939813

Group type: EXPERIMENTAL
Intervention: High-intensity CBT delivered by a fully qualified cognitive behavioural therapist
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Low-intensity guided self-help delivered by a registered nurse
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Self-help only without therapist support
Number of subjects: 60

Group type: COMPARATOR
Intervention: Treatment as usual control condition
Number of subjects: 60
Study: 22357130

Group type: EXPERIMENTAL
Intervention: BDP/F HFA pMDI
Number of subjects: 568
Study: 20412459

Group type: COMPARATOR
Intervention: Caudal levobupivacaine 0.125% (group L)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Caudal tramadol 1.5 mg.kg(‐1) (group T)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Mixture of both (group LT)
Number of subjects: 63
Study: 17680827

Group type: EXPERIMENTAL
Intervention: BRAD-3/5 monoclonal anti-D IgG (MAD)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: rBRAD-3/5 recombinant anti-D IgG (RAD)
Number of subjects: 6
Study: 15788064

Group type: EXPERIMENTAL
Intervention: Adaptation Training Programme (ATP) plus usual care
Number of subjects: 57

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 57
Study: 12120807

Group type: EXPERIMENTAL
Intervention: Valerian treatment
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 9807293

Group type: EXPERIMENTAL
Intervention: Educational booklet intervention
Number of subjects: 150

Group type: COMPARATOR
Intervention: Information leaflet (control)
Number of subjects: 150
Study: 9179964

Group type: EXPERIMENTAL
Intervention: Aqueous propolis extract NIVCRISOL administered during the cold season 1994-1995
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 2712694

Group type: EXPERIMENTAL
Intervention: Covert sensitization
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Imaginal desensitization
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Imaginal desensitization plus medroxyprogesterone
Number of subjects: 6

Group type: COMPARATOR
Intervention: Not applicable (control group not specified)
Number of subjects: 6
Study: 339438

Group type: EXPERIMENTAL
Intervention: Horse antilymphoblast globulin (ALG) 20 mg/kg/day for 10 days
Number of subjects: 45

Group type: COMPARATOR
Intervention: Human IgG 20 mg/kg/day for 10 days (Control)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Horse antilymphoblast globulin (ALG)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Human IgG (Control)
Number of subjects: 45
Study: 31688793

Group type: EXPERIMENTAL
Intervention: Prehospital plasma
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: 4 to 7 units of red cells
Number of subjects: 501

Group type: COMPARATOR
Intervention: Massive transfusion (MT)
Number of subjects: 501
Study: 30502094

Group type: EXPERIMENTAL
Intervention: Psychiatric disorder
Number of subjects: 9309

Group type: COMPARATOR
Intervention: No psychiatric disorder
Number of subjects: 9309
Study: 27941526

Group type: EXPERIMENTAL
Intervention: Epigallocatechin gallate (EGCG) with rt‐PA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo with rt‐PA
Number of subjects: 0
Study: 25711509

Group type: EXPERIMENTAL
Intervention: Aripiprazole once-monthly 400 mg (AOM 400)
Number of subjects: 710

Group type: COMPARATOR
Intervention: Placebo (in the 52-week study)
Number of subjects: 710

Group type: COMPARATOR
Intervention: Active control (in the 38-week study)
Number of subjects: 710
Study: 23210916

Group type: COMPARATOR
Intervention: Adper Scotchbond Multi-Purpose (MP, 3M ESPE) - Control Group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Adper Easy Bond (EB, 3M ESPE)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Experimental Adper Easy Bond without the Vitrebond Co-polymer (EBnoCP, 3M ESPE)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Adper Single Bond Plus (SB, 3M ESPE)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Experimental Adper Single Bond Plus without CP (SBnoCP, 3M ESPE)
Number of subjects: 60
Study: 21883874

Group type: EXPERIMENTAL
Intervention: Active PENS therapy
Number of subjects: 31

Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 31
Study: 18638040

Group type: EXPERIMENTAL
Intervention: Soft hand brace (MANU)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Wrist splint (CAMP TIELLE)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 120
Study: 16762076

Group type: EXPERIMENTAL
Intervention: Dietary nucleotide supplementation (500 mg capsule three times a day for 56 days)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo (500 mg capsule three times a day for 56 days)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Baseline (no intervention)
Number of subjects: 37
Study: 15017564

Group type: EXPERIMENTAL
Intervention: Standard dose cisplatin (100 mg/m2/cycle), etoposide, and bleomycin (PEB) chemotherapy for Stage I‐II patients
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: High-dose cisplatin (200 mg/m2/cycle) with etoposide and bleomycin (HDPEB) for Stage III‐IV patients
Number of subjects: 131
Study: 10739900

Group type: EXPERIMENTAL
Intervention: Novel picture encoding task to activate hippocampus for 2 min
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Finger sequencing task to activate primary motor cortex
Number of subjects: 0
Study: 9088685

Group type: EXPERIMENTAL
Intervention: salmeterol
Number of subjects: 33

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 33
Study: 8468734

Group type: EXPERIMENTAL
Intervention: Chemotherapy (Cisplatin + 5‐Fu) and radiation
Number of subjects: 95

Group type: COMPARATOR
Intervention: Radiation only
Number of subjects: 95
Study: 2948826

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) infusion at 1.5 pmol X kg‐1 X min‐1 for 30 min followed by 15 pmol X kg‐1 X min‐1 for a further 30 min
Number of subjects: 6

Group type: COMPARATOR
Intervention: Matching vehicle infusions (control)
Number of subjects: 6
Study: 3154686

Group type: EXPERIMENTAL
Intervention: Molsidomine (12 to 24 mg/day orally; initial 20 mg i.v. followed by infusion of 1 to 4 mg/hour)
Number of subjects: 20
Study: 30877209

Group type: EXPERIMENTAL
Intervention: Increased treatment
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Unchanged treatment
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Reduced treatment
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Treatment with tocilizumab for GCA and tumor necrosis factor inhibitors for TA
Number of subjects: 52
Study: 30917815

Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric assessments and case conferencing
Number of subjects: 19
Study: 29142236

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-α) therapy with a scoring model composed of miR-210, miR-22, and alanine aminotransferase (ALT)
Number of subjects: 112
Study: 25441251

Group type: EXPERIMENTAL
Intervention: TLC diet with 0.5 cup of soy nuts (25 g of soy protein and 101 mg of aglycone isoflavones)
Number of subjects: 60

Group type: COMPARATOR
Intervention: TLC diet alone (control)
Number of subjects: 60
Study: 23328663

Group type: EXPERIMENTAL
Intervention: Human computation (HC) method
Number of subjects: 120

Group type: COMPARATOR
Intervention: Informal consensus (IC) method
Number of subjects: 120
Study: 21699432

Group type: COMPARATOR
Intervention: Volume-Controlled Ventilation (VCV)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Pressure-Controlled Ventilation (PCV)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Both VCV and PCV
Number of subjects: 34
Study: 18504236

Group type: EXPERIMENTAL
Intervention: Flavon Max product
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16426961

Group type: EXPERIMENTAL
Intervention: Micronutrient-enriched beverage
Number of subjects: 268

Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 268
Study: 12659385

Group type: COMPARATOR
Intervention: Nebulized albuterol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nebulized albuterol plus ipratropium
Number of subjects: 0
Study: 11153621

Group type: EXPERIMENTAL
Intervention: Enteral feeding solution enriched with vitamins A (67 microg/dL), C (13.3 mg/dL), and E (4.94 mg/dL)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Isocaloric and isonitrogenous control solution
Number of subjects: 51
Study: 9244718

Group type: EXPERIMENTAL
Intervention: TEPT-guided antiarrhythmic therapy (using flecainide, propafenone, or sotalol)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Empiric antiarrhythmic therapy (using flecainide, propafenone, or sotalol)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: TEPT-guided therapy
Number of subjects: 160
Study: 1543305

Group type: EXPERIMENTAL
Intervention: Supervised fitness walking and patient education
Number of subjects: 102

Group type: COMPARATOR
Intervention: Standard routine medical care
Number of subjects: 102
Study: 3897351

Group type: EXPERIMENTAL
Intervention: +1.00 D. add group
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: +2.00 D. add group
Number of subjects: 213

Group type: COMPARATOR
Intervention: Single vision (standard treatment) group
Number of subjects: 213
Study: 31892611

Group type: EXPERIMENTAL
Intervention: 600 IUs/day of oral vitamin D3
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 4,000 IUs/day of oral vitamin D3
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 10,000 IUs/day of oral vitamin D3
Number of subjects: 20
Study: 29945555

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 84
Study: 27006113

Group type: EXPERIMENTAL
Intervention: Dopamine D2 receptor antagonist (sulpiride 400 mg)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Pathological Gamblers
Number of subjects: 44

Group type: COMPARATOR
Intervention: Healthy Controls
Number of subjects: 44
Study: 25015680

Group type: COMPARATOR
Intervention: 0 g of oral tyrosine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 2 g of oral tyrosine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 5 g of oral tyrosine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 10 g of oral tyrosine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Maternal plasma tyrosine
Number of subjects: 24
Study: 21990343

Group type: EXPERIMENTAL
Intervention: Disease Management Programme (DMP) for diabetes type 2
Number of subjects: 1489
Study: 20187278

Group type: EXPERIMENTAL
Intervention: Repeated FMD procedures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repeated FMD procedures and acute aerobic exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lean controls
Number of subjects: 0
Study: 18753801

Group type: EXPERIMENTAL
Intervention: Aroma hand massage
Number of subjects: 58

Group type: COMPARATOR
Intervention: General oil hand massage
Number of subjects: 58
Study: 17283929

Group type: EXPERIMENTAL
Intervention: Familiarisation with the transparency display (experiment 1)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Familiarisation with the non-transparent display (experiment 2)
Number of subjects: 24
Study: 11810087

Group type: EXPERIMENTAL
Intervention: Severe gestational hypertension (without proteinuria)
Number of subjects: 598

Group type: COMPARATOR
Intervention: Mild preeclampsia
Number of subjects: 598

Group type: COMPARATOR
Intervention: Normotensive/mild gestational hypertension
Number of subjects: 598
Study: 10808389

Group type: EXPERIMENTAL
Intervention: Celiprolol (200 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Metoprolol (50 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Atenolol (25 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 7596852

Group type: EXPERIMENTAL
Intervention: Echocardiography
Number of subjects: 18
Study: 2191592

Group type: EXPERIMENTAL
Intervention: Sodium tetradecyl sulfate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ethanolamine oleate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Polidocanol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 0
Study: 7210690

Group type: EXPERIMENTAL
Intervention: Oxazepam (Anxiolit retard)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No administration of Oxazepam
Number of subjects: 0
Study: 28859993

Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical ciprofloxacin (gel)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Topical ciprofloxacin (other formulations)
Number of subjects: 0
Study: 26081567

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa targeting hemoglobin (Hb) levels of 11-13 g/dL
Number of subjects: 498

Group type: COMPARATOR
Intervention: Low Hb group maintained at 9.0-11.0 g/dL using epoetin alfa
Number of subjects: 498
Study: 24614074

Group type: EXPERIMENTAL
Intervention: Naso-gastric infusion of chocolate milk (stomach distention + nutrients)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Naso-gastric infusion of water (stomach distention)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Ingestion of chocolate milk (stomach distention + nutrients + oral exposure)
Number of subjects: 14
Study: 22036776

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 100 U
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 150 U
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 20527136

Group type: EXPERIMENTAL
Intervention: 85% formic acid in distilled water solution
Number of subjects: 34

Group type: COMPARATOR
Intervention: Distilled water (placebo)
Number of subjects: 34
Study: 16782320

Group type: EXPERIMENTAL
Intervention: Chronic Respiratory Questionnaire (CRQ)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: St. Georges Respiratory Questionnaire (SGRQ)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Generic measures (SF-36, Feeling Thermometer, Standard Gamble, Health Utilities index 3)
Number of subjects: 177
Study: 16272420

Group type: EXPERIMENTAL
Intervention: Telephone mode of G-CAHPS survey
Number of subjects: 880

Group type: COMPARATOR
Intervention: Mail mode of G-CAHPS survey
Number of subjects: 880
Study: 11906502

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (500 mg single dose)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Norfloxacin (400 mg twice daily for 3 days)
Number of subjects: 226
Study: 9759984

Group type: EXPERIMENTAL
Intervention: Captopril (25 mg)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Captopril (25 mg twice daily for 3 months)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Normotensive control group
Number of subjects: 23
Study: 7799050

Group type: EXPERIMENTAL
Intervention: Calcium mupirocin ointment administered intranasally for five days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 3197372

Group type: EXPERIMENTAL
Intervention: Lowering one foot 50 cm below heart level
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Lumbar sympathetic blockade (epidural anaesthesia)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Lowering one foot below heart level
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Local nervous blockade (lignocaine 3.7 x 10(‐4)‐7.4 x 10(‐2) mol/l)
Number of subjects: 102
Study: 28457980

Group type: COMPARATOR
Intervention: Fresh Frozen Plasma (FFP) 15 mL/kg of bodyweight
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Coagulation Factor Concentrates (CFC) primarily fibrinogen concentrate 50 mg/kg of bodyweight
Number of subjects: 100

Group type: COMPARATOR
Intervention: Fresh Frozen Plasma (FFP)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Coagulation Factor Concentrates (CFC)
Number of subjects: 100
Study: 25481576

Group type: EXPERIMENTAL
Intervention: Usual services plus LVSMP (8-week group programme facilitated by low vision counsellors)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Usual services
Number of subjects: 153
Study: 23523131

Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 175

Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Buprenorphine dropouts
Number of subjects: 175

Group type: COMPARATOR
Intervention: Methadone dropouts
Number of subjects: 175
Study: 21263100

Group type: EXPERIMENTAL
Intervention: Biweekly intravenous dactinomycin 1.25 mg/m²
Number of subjects: 216

Group type: COMPARATOR
Intervention: Weekly intramuscular (IM) methotrexate 30 mg/m²
Number of subjects: 216
Study: 19916640

Group type: EXPERIMENTAL
Intervention: Negative emotion condition
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control condition (positive or no emotions)
Number of subjects: 4
Study: 16492848

Group type: EXPERIMENTAL
Intervention: Acupressure bands on the P6 acupoint
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo bands on the P6 acupoint
Number of subjects: 110
Study: 15042325

Group type: EXPERIMENTAL
Intervention: 18F-desmethoxyfallypride (18F-DMFP) PET imaging after injection of 180-200 MBq
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 18F-DMFP PET imaging
Number of subjects: 51

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 51
Study: 11053269

Group type: EXPERIMENTAL
Intervention: Partial spectacle correction
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Untreated group
Number of subjects: 148

Group type: COMPARATOR
Intervention: Control group (no significant refractive errors)
Number of subjects: 148
Study: 9126305

Group type: EXPERIMENTAL
Intervention: 5'-DFUR (mean 9,000 mg) preoperatively
Number of subjects: 42

Group type: COMPARATOR
Intervention: No anticancer agents (Control group B)
Number of subjects: 42
Study: 7984719

Group type: EXPERIMENTAL
Intervention: Popping air capsules for 5 minutes (experimental group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 0
Study: 2720864

Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 2995

Group type: EXPERIMENTAL
Intervention: Pollen diet during irradiation
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (no pollen added to diet)
Number of subjects: 15
Study: 31862192

Group type: EXPERIMENTAL
Intervention: ETT twisting technique
Number of subjects: 540

Group type: COMPARATOR
Intervention: Static ETT technique
Number of subjects: 540
Study: 31288829

Group type: EXPERIMENTAL
Intervention: EMPOWER intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 60
Study: 28434406

Group type: EXPERIMENTAL
Intervention: EFV (abacavir + lamivudine + efavirenz)
Number of subjects: 156

Group type: COMPARATOR
Intervention: LPV (zidovudine + abacavir + lamivudine + lopinavir/ritonavir)
Number of subjects: 156
Study: 24274771

Group type: EXPERIMENTAL
Intervention: Cocoa treatment (37 g/d of dark chocolate and a sugar-free cocoa beverage, total cocoa = 22 g/d, total flavanols = 814 mg/d)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control treatment (low-flavanol chocolate bar and a cocoa-free beverage, total flavanols = 3 mg/d)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cocoa treatment
Number of subjects: 30
Study: 22170713

Group type: EXPERIMENTAL
Intervention: Intensive glycemic control (IGC; n=20; glucose goal, 80‐140 mg/dl)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Conventional glycemic control (CGC; n=20; glucose goal, 180‐200 mg/dl)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Glucose-insulin-potassium (GIK; n=10; glucose goal, 180‐200 mg/dl)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (25 patients with glycemia below 140 mg/dl)
Number of subjects: 75
Study: 20691307

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 6166

Group type: EXPERIMENTAL
Intervention: CABG only
Number of subjects: 6166

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) only
Number of subjects: 6166

Group type: EXPERIMENTAL
Intervention: CABG+PCI
Number of subjects: 6166

Group type: COMPARATOR
Intervention: Nonrevascularized patients
Number of subjects: 6166
Study: 17505990

Group type: EXPERIMENTAL
Intervention: Combination of famotidine (10 mg) and omeprazole (20 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Omeprazole (20 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Famotidine (10 mg)
Number of subjects: 0
Study: 16173416

Group type: EXPERIMENTAL
Intervention: ROM regimen (one-dose regimen)
Number of subjects: 51

Group type: COMPARATOR
Intervention: PB-MDT regimen (standard regimen)
Number of subjects: 51
Study: 12417288

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 325

Group type: COMPARATOR
Intervention: Simvastatin 40 mg
Number of subjects: 325
Study: 10520779

Group type: EXPERIMENTAL
Intervention: Enalapril 5 mg daily for 4 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 32
Study: 7712392

Group type: EXPERIMENTAL
Intervention: Lactitol
Number of subjects: 41

Group type: COMPARATOR
Intervention: Lactulose
Number of subjects: 41
Study: 2502950

Group type: EXPERIMENTAL
Intervention: Topical mupirocin applied three times daily
Number of subjects: 75

Group type: COMPARATOR
Intervention: Oral erythromycin ethylsuccinate (30 to 50 mg/kg per day)
Number of subjects: 75